Proteomic and mechanistic studies reveal that AKT inhibition alone is insufficient, whereas dual Src and AKT inhibition synergistically induces apoptosis and suppresses growth in phosphatase and tensin homolog–deficient cancers, highlighting a promising therapeutic strategy. The gene discussed is AKT1; the disease is cancer.